Eli Lilly Gets Expanded FDA EUA for Covid-19 Treatment for Some High-Risk Individuals
September 16 2021 - 5:16PM
Dow Jones News
By Kimberly Chin
Eli Lilly & Co. said the U.S. Food and Drug Administration
expanded the company's emergency use authorization for its
combination Covid-19 treatment to include some individuals who may
have a high risk of infection after being exposed to someone with
the disease.
The drugs bamlanivimab and etesevimab, which are administered
together, could be used to treat children who are 12 years of age
or older who haven't been fully vaccinated or people who may not
develop an adequate immune response after being fully vaccinated,
the company said.
With the expanded authorization, the combination treatment could
be used as a preventive treatment in an institutional setting, such
as in a nursing home or prison, for certain individuals who may be
exposed to someone with Covid-19 or who have a high risk of
exposure, the company said.
"We're pleased that this expansion will help us provide antibody
therapies as post-exposure prophylaxis to help prevent the spread
of Covid-19 to some of the most at-risk individuals in the U.S.,"
Eli Lilly's Chief Science and Medical Officer Daniel Skovronsky
said in prepared remarks.
Post-exposure prophylaxis refers to treatments that can be taken
to prevent a virus after a potential exposure.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
September 16, 2021 17:01 ET (21:01 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Apr 2023 to Apr 2024